SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

FRASSOLDATI, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.191
AS - Asia 4.981
EU - Europa 4.405
SA - Sud America 808
AF - Africa 133
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 3
Totale 19.537
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.990
FI - Finlandia 2.058
SG - Singapore 1.979
CN - Cina 1.082
BR - Brasile 656
IT - Italia 602
VN - Vietnam 541
DE - Germania 425
HK - Hong Kong 419
GB - Regno Unito 248
TR - Turchia 207
PL - Polonia 199
UA - Ucraina 170
BD - Bangladesh 152
FR - Francia 150
SE - Svezia 142
IN - India 126
RU - Federazione Russa 120
JP - Giappone 110
ID - Indonesia 102
MX - Messico 100
CA - Canada 73
NL - Olanda 57
AR - Argentina 53
ZA - Sudafrica 49
IQ - Iraq 42
TW - Taiwan 42
BE - Belgio 39
ES - Italia 37
AT - Austria 35
PK - Pakistan 24
EC - Ecuador 21
CL - Cile 19
LT - Lituania 19
CO - Colombia 17
SA - Arabia Saudita 17
UZ - Uzbekistan 17
MA - Marocco 16
AU - Australia 15
CZ - Repubblica Ceca 15
EG - Egitto 14
MY - Malesia 14
IE - Irlanda 13
VE - Venezuela 13
PH - Filippine 12
PY - Paraguay 12
PE - Perù 11
ET - Etiopia 10
KR - Corea 10
TN - Tunisia 10
AE - Emirati Arabi Uniti 9
AL - Albania 9
DZ - Algeria 9
KE - Kenya 9
OM - Oman 9
CH - Svizzera 8
PT - Portogallo 8
CR - Costa Rica 7
DK - Danimarca 7
JO - Giordania 7
IR - Iran 6
KZ - Kazakistan 6
LV - Lettonia 6
RO - Romania 6
HU - Ungheria 5
IL - Israele 5
PS - Palestinian Territory 5
TH - Thailandia 5
CI - Costa d'Avorio 4
GR - Grecia 4
JM - Giamaica 4
KG - Kirghizistan 4
LB - Libano 4
NP - Nepal 4
PA - Panama 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
AZ - Azerbaigian 3
BA - Bosnia-Erzegovina 3
BG - Bulgaria 3
KW - Kuwait 3
MD - Moldavia 3
NG - Nigeria 3
NO - Norvegia 3
QA - Qatar 3
RS - Serbia 3
XK - ???statistics.table.value.countryCode.XK??? 3
BB - Barbados 2
BH - Bahrain 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GT - Guatemala 2
HN - Honduras 2
MU - Mauritius 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
AM - Armenia 1
AO - Angola 1
Totale 19.520
Salva come PNG Salva come JPEG
Città #
Helsinki 2.015
Singapore 1.218
Ashburn 1.183
Fairfield 868
Woodbridge 751
San Jose 518
Houston 470
Santa Clara 420
Chandler 416
Hong Kong 408
Beijing 358
Seattle 358
Wilmington 330
Ann Arbor 321
Cambridge 304
Jacksonville 255
Warsaw 196
Munich 187
New York 177
Ho Chi Minh City 169
Los Angeles 161
Izmir 160
Dallas 133
Hanoi 123
Princeton 104
Tokyo 99
Council Bluffs 98
Lauterbourg 98
Nanjing 97
Ferrara 88
Jakarta 84
Milan 70
Shanghai 62
São Paulo 61
Mexico City 56
London 54
Boardman 53
Chicago 53
San Diego 53
The Dalles 44
Orem 42
Brussels 39
Columbus 39
Nanchang 37
Falls Church 35
Atlanta 33
Bologna 33
Dearborn 32
Hebei 32
Buffalo 29
Chennai 28
Brooklyn 27
Tianjin 27
Nuremberg 26
Dong Ket 25
Johannesburg 25
Montreal 25
Shenyang 25
Haiphong 24
Stockholm 24
Poplar 23
Redwood City 23
Turku 23
Changsha 22
Des Moines 22
Guangzhou 21
Boston 20
Da Nang 20
Naples 19
Phoenix 19
Rio de Janeiro 19
Denver 18
Mumbai 18
Norwalk 18
Charlotte 17
Rome 17
Tashkent 17
Toronto 17
Biên Hòa 16
Bremen 16
Frankfurt am Main 16
Baghdad 15
Belo Horizonte 15
Moscow 15
Vienna 15
Amsterdam 14
Shenzhen 14
Falkenstein 13
Jiaxing 13
Manchester 13
Hefei 12
San Francisco 12
Verona 12
Kunming 11
Mountain View 11
Pittsburgh 11
Querétaro 11
Salt Lake City 11
Salvador 11
Addison 10
Totale 13.920
Salva come PNG Salva come JPEG
Nome #
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study 2.086
Absolute quantification of cell-free microRNAs in cancer patients 333
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 317
Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR 302
Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma 301
High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy 297
Gastrointestinal stromal tumors and other malignancies: A case series 274
miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model 266
Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study 263
Reversibility of Left Ventricle Longitudinal Strain Alterations Induced by Adjuvant Therapy in Early Breast Cancer Patients 263
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma 238
Patient and Health Care Professional Perspectives: A Case Study of the Lung Cancer Integrated Care Pathway 238
miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models 237
18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready? 233
HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights 233
Prevalence of malnutrition in patients at first medical oncology visit: The PreMiO study 233
Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy 230
Multidisciplinary management improves survival at 1 year after surgical treatment for non-small-cell lung cancer: a propensity score-matched study 225
Current views on anthracycline cardiotoxicity 225
Il protocollo Diagnostico-Terapeutico e Assistenziale per il carcinoma mammario della Regione Emilia-Romagna. I edizione 222
Synchronous papillary carcinoma and hemangiopericytoma with lung metastases 216
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab 216
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: Implications for personalised treatment 215
Estrogen receptor mutation: a new strategy to overcome endocrine resistance 207
Ovarian endometrioid adenocarcinoma with a yolk sac tumor component in a postmenopausal woman: Case report and review of the literature 203
The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: How much does it cost? A retrospecive economic assessment from a single-center experience 202
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 201
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion 194
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 192
Impressive response to dose-dense chemotherapy in a patient with NUT midline carcinoma 186
Adjuvant hormonal therapy and fertility preservation in premenopausal breast cancer: A survey among Italian oncologists 182
Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy 181
Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancer 180
Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB trial) 177
Double-blind, placebo-controlled, multicenter, randomized, phase IIB neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer 176
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 171
Monitoring Somatic Genetic Alterations in Circulating Cell-Free DNA/RNA of Patients with "Oncogene-Addicted" Advanced Lung Adenocarcinoma: A Real-World Clinical Study 169
Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective 169
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 166
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 164
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial 160
Circular RNAs Could Encode Unique Proteins and Affect Cancer Pathways 159
Trends in net survival from liver cancer in six European Latin countries: results from the SUDCAN population-based study 159
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 159
The role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) in suspected recovery of breast cancer disease: comparison with Radiological Imaging and impact on patient management 159
Can irinotecan dose reduction according to ugt1a1 genotype avoid severe toxicities? 159
Clinical-diagnostic relevance of breast “incidentaloma” detected during 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography: Correlation with radiological imaging and histopathology 156
Tumor infiltrating lymphocytes in triple negative breast cancer and correlations with prognosis 154
Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer 153
Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients: Efficacy and Safety of Combination 153
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 150
Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer 149
Letrozole versus letrozole plus lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: A double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB) 149
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results 149
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: Results of the PerELISA neoadjuvant study 149
Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM) 149
Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable? 148
Primary systemic therapy in operable breast cancer: Clinical data and biological fall-out 148
Changes of biological features in breast cancer cells determined by primary chemotherapy 148
Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients 147
The role of (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (PET/CT) in patients with breast cancer recurrence: a comparison to conventional imaging (CI) techniques and clinical impact on patient management 147
Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke 147
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials 146
Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study 146
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study 145
HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results 144
Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives 143
Risk of second cancer in patients with hairy cell leukemia: long-term follow-up 142
The promher study: An observational Italian study on adjuvant therapy for her2-positive, pT1a-b pN0 breast cancer 140
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 140
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer 139
Primary systemic therapy for operable breast cancer: A review of clinical trials and perspectives 138
The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients 138
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278) 138
Immediate administration of zoledronic acid reduces aromatase inhibitorassociated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial 137
Predictive value of biologic parameters for primary chemotherapy in operable breast cancer 137
Erratum: miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models 136
Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women? 136
The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer 136
The Molecular Networks of microRNAs and Their Targets in the Drug Resistance of Colon Carcinoma 133
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting 132
Gene expression profiling in breast cancer: A clinical perspective 131
Pattern of distant recurrence according to the molecular subtypes identified by immunohistochemistry in women with early breast cancer 128
Impact on the long-term prognosis of FDG PET/CT in luminal-A and luminal-B breast cancer 128
Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report 125
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 120
Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: Extending endocrine sensitivity 120
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 119
Gli standard oncologici nel Percorso Diagnostico Terapeutico Assistenziale del paziente con carcinoma del colon: Dati del biennio 2009-2010 presso l'UO di Oncologia Clinica dell'AOU di Ferrara 119
How to fish a good micro-marker out from a worthless lake: The case of cell-free miR-181a-5p and breast cancer 119
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer 119
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 119
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study 116
Italian cohort of the nivolumab EAP in squamous NSCLC: Efficacy and safety in patients with CNS metastases 108
Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study 102
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): An exploratory, open-label, phase 2 study 100
Liquid biopsy testing can improve selection of advanced non-small-cell lung cancer patients to rechallenge with gefitinib 95
Pulmonary strongyloidiasis mimicking cancer symptoms: A case of hyperinfection in a patient with metastatic lung cancer 94
Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? 92
Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study 91
Totale 18.925
Salva come PNG Salva come JPEG
Categoria #
all - tutte 91.907
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 91.907
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021137 0 0 0 0 0 0 0 0 0 0 0 137
2021/2022844 33 48 53 22 26 109 76 42 57 109 48 221
2022/20231.024 116 59 60 112 134 133 49 124 119 11 71 36
2023/2024582 55 70 27 19 42 88 25 52 12 15 19 158
2024/20252.776 70 76 229 119 345 276 154 150 491 275 310 281
2025/20269.187 636 246 567 866 1.179 454 877 475 2.564 792 459 72
Totale 19.804